When GLP-1s Enter the Psoriasis Treatment Picture

Updated:Nov 19, 2026

About this video

When a patient taking a GLP-1 medication is considering icotrokinra for plaque psoriasis, there’s a question worth bringing up in the visit. If the GLP-1 slows gastric emptying, could that change how much of the oral psoriasis drug reaches the bloodstream? Graham Litchman, DO, walks through a pooled post hoc analysis of the phase 3 ICONIC studies. He covers the week 16 skin responses, the adverse events, and the finding he considers most relevant to that conversation: estimated icotrokinra exposure was similar with and without GLP-1 use. He also explains why, in a small post hoc subgroup, there’s more uncertainty for a patient who has just started a GLP-1 or is increasing the dose.